Therapeutic effect of intensive anti -platelet therapy on patients with acute myocardial infarction com-plicated diabetes mellitus
10.3969/j.issn.1008-0074.2016.01.24
- VernacularTitle:强化抗血小板治疗对急性心肌梗死合并糖尿病患者的疗效
- Author:
Dewei WANG
;
Jie HUANG
;
Haiying YANG
- Publication Type:Journal Article
- Keywords:
Myocardial infarction;
Diabetes mellitus,type 2;
Platelet aggregation inhibitors;
Treatment outcome
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2016;25(1):84-87
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze therapeutic effect and safety of triple intensive anti -platelet therapy on patients with acute myocardial infarction (AMI) complicated type 2 diabetes mellitus (T2DM) .Methods:A total of 100 AMI + T2DM patients were enrolled and equally divided into routine treatment group (received aspirin and clopi‐dogrel treatment based on routine treatment ) and tirofiban group (received tirofiban based on routine treatment group) .Platelet count (PLT) ,platelet activating factor (PAF) ,prothrombin time (PT) ,activated partial thrombo‐plastin time (APTT) ,fibrinogen (Fg) ,left ventricular ejection fraction (LVEF) ,left ventricular fractional short‐ening (LVFS) ,stroke volume (SV) and therapeutic effect were measured and compared between two groups .All patients were followed up for six months ,incidence rates of major adverse cardiovascular events (MACE) and vari‐ous hemorrhage events were compared between two groups .Results :Compared with routine treatment group ,there were significant reductions in PLT [(18.2 ± 2.5) 109/L vs .(15.8 ± 1.4) 109/L] and PAF [(138.6 ± 10.2)μg/L vs . (61.5 ± 3.1)μg/L] (P<0.05 ,<0.01);and significant rise in LVEF [ (56.9 ± 5.2)% vs .(64.2 ± 4.6)% ] ,LVFS [ (30.4 ± 3.3)% vs .(39.8 ± 4.5)% ] ,SV [ (43.2 ± 3.4) ml vs .(74.5 ± 4.6) ml] and total effective rate (76.0%vs .96.0% ) in tirofiban group , P<0.05 all .After six-month follow-up ,there were no significant difference in incidence rates of MACE and bleeding between two groups , P>0.05 all .Conclusion:Therapeutic effect of triple in‐tensive anti-platelet therapy is significant in AMI + T2DM patients ,and its adverse reactions and prognosis have no difference with those of dual anti -platelet therapy .
